Comparative Pharmacology
Head-to-head clinical analysis: INVEGA SUSTENNA versus PALIPERIDONE PALMITATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA SUSTENNA versus PALIPERIDONE PALMITATE.
INVEGA SUSTENNA vs PALIPERIDONE PALMITATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is an atypical antipsychotic that acts primarily as a central dopamine type 2 (D2) receptor antagonist and serotonin type 2A (5-HT2A) receptor antagonist. It also blocks α1- and α2-adrenergic receptors and H1 histamine receptors.
Paliperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also blocks alpha-2 adrenergic and H1 histaminergic receptors.
Initiate with 234 mg intramuscular injection on day 1, then 156 mg on day 8, both deltoid. Maintenance: 117 mg monthly (range 39-234 mg) via deltoid or gluteal injection. Dosing based on paliperidone palmitate.
Paliperidone palmitate is administered intramuscularly. Initial dose: 150 mg eq. on day 1 and 100 mg eq. on day 8, both in the deltoid muscle. Maintenance dose: 75 mg eq. monthly (range 25–150 mg eq.) administered in the deltoid or gluteal muscle.
None Documented
None Documented
Terminal elimination half-life ranges from 25 to 49 days (mean ~38 days) for deltoid injection and 30 to 50 days (mean ~45 days) for gluteal injection, supporting monthly dosing.
Terminal elimination half-life: 25-49 days (mean ~30 days) for IM injection; allows monthly dosing
Renal: approximately 59-80% as unchanged drug and metabolites, with about 1% unchanged; biliary/fecal: approximately 20-41% primarily as metabolites.
Renal: 80% as unchanged drug and metabolites; fecal: 11%
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic